This study is observing premature infants who have experienced bleeding in the brain (germinal matrix-intraventricular hemorrhage or GM-IVH) and/or developed fluid buildup in the brain (post-hemorrhagic hydrocephalus or PHH). Researchers are using a special technology called FDNIRS-DCS to measure blood flow and how the brain uses oxygen (CMRO2) at the bedside. They want to see if these measurements can better show how severe the conditions are and how well treatments for hydrocephalus, like ETV/CPC surgery, are working. The study includes infants born between 24-32 weeks gestation, up to 12 months old, who have been diagnosed with GM-IVH. The goal is to compare these infants to healthy babies and those with hydrocephalus from other causes.

Study design

This is an observational study, meaning researchers are watching and collecting information without giving any new treatments. It plans to include 70 participants.

What's involved

Participants will have their cerebral oxygen metabolism (CMRO2) measured. The study will follow participants for up to 2 years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 2 years to measure CMRO2.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.